Happening now! #Tandem24 Poster reception. Stop by poster #284 to say hello and learn about Mayo Clinic’s outpatient program for #CARTcell and #BsAb Radhika Bansal Rakshit (She/Her) Yi Lin Jonas Paludo Mayo Clinic Comprehensive Cancer Center #mmsm #lymsm #leuksm ASTCT

The Spring 2024 FDA-ASCO Fellows Day Workshop was a great success! We always enjoy meeting talented people at the start of their careers who represent the future of oncology! #OCEProjectSocrates #MedEd Tatiana Prowell, MD Jennifer Gao @suparnawedam Timil Patel, MD Rick Pazdur

sciencedirect.com/science/articl…

#mmsm How to counsel patients about Cilta Cel using the data from CARTITUDE-4 and FDA ODAC meeting for earlier use With data of Cilta cel and Ide cel, assuming having access to both for a given patient, I will personally chose Cilta cel (I explained this before) 🧵

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma. U.S. FDA #lymsm onclive.com/view/fda-grant…

Come join me at 1630 CEST or 930 CST at Goya 1 at #EHA2024 at the Stem Cell- Transplant 2 to see me discuss how mixed donor chimerism after transplant affects relapse after PTCy. Mayo Clinic Transplant Mayo Clinic Hematology-Oncology Fellowship Mayo Clinic Comprehensive Cancer Center #bmtsm #ptcy

Learn about the effects of donor chimerism after allogeneic SCT and #PTCy with Dr. Graham at the Oral Abstract session on stem cell transplant at EHA2024 today! #BMTsm

Cure is a simple word. But there is confusion when it comes to cancer. What cure is in cancer, and what we should aspire for? When can we say that a given type of cancer is curable? Thread 1/

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma ow.ly/zkyr50SKEGV #immunobiologyandimmunotherapy #lymphoidneoplasia

Congratulations and welcome to WiL's new *Sub-Committee Emerging Collaborators* 🌏🩺 Allison Barraclough @OncDocBock Supriya Gupta, MD Avyakta Kallam Swetha Kambhampati Patrizia Mondello, MD, PhD, MSc Priyanka Pophali, MD Tarsheen Sethi, MD, MSCI Pallawi Torka Yun Kyoung Ryu

Patients excluded from clinical trials of DLBCL are at a higher risk of dying from lymphoma when treated with standard-of-care therapy. ow.ly/Ihbt50T8HsO #healthservicesandoutcomes #lymphoidneoplasia

Doctors at the University of Minnesota Adult Blood and Marrow Transplant and Cellular Therapy Program (BMTCT) Program are world-renowned experts in blood and bone marrow transplantation and cellular therapy.

In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS

⚕️ Women in Lymphoma - [email protected] Steering Committee members, advocates, sponsors and supporters from all over the world🌍networking and sharing connections, initiatives and experience at #ASH24 #lymsm #lymphoma ASH

Had a great time presenting our research on cytokine trends as #biomarkers to predict the development of post CAR-T hyperinflammatory states and guide treatment. Exciting discussion and collaboration ahead! Grateful for the incredible mentorship of Yi Lin #Tandem25 ASTCT

On May 8, the U.S. FDA lifted a clincal hold on an active IND application for the tabelecleucel, allowing the resumption of clinical research for patients with EBV+ post-transplant lymphoproliferative disease after HSCT or solid organ transplant. hubs.li/Q03pMnCL0

Happening now #EHA25 poster session. Dr. Melinda Tan Mayo Clinic Comprehensive Cancer Center presents cytokine and cellular immune profile distinctions among CRS vs low grade vs high grade IEC-HS post #CART #lymsm #mmsm predictors at early onset help clinicians tailor management. ASTCT Supriya Gupta, MD

Excellent news for our CAR-T patients! The FDA has relaxed the post-infusion monitoring requirement near the treatment center and driving restrictions down to 2 weeks. This change reflects growing safety data with CAR-T! #lymsm #mmsm #leuksm fda.gov/vaccines-blood…

This study compares chimerism kinetics in patients receiving PTCy vs methotrexate-based GVHD prophylaxis after #alloHCT. Among patients undergoing myeloablative conditioning and receiving PTCy, mixed CD3 chimerism is associated with an inferior RFS. ow.ly/LJmn50WU0tH

We are increasing realizing the amount of CMV reaction and viremia in patients receiving CAR-T, therefore CMV surveillance, even past D30 is critical to reduce these complications for our patients.